pharmaand GmbH
Climate Impact & Sustainability Data (2022, 2023)
Reporting Period: 2022
Environmental Metrics
Total Carbon Emissions:1425.17 tCO2e/year
Scope 1 Emissions:4.51 tCO2e/year (pharma&), 1200.00 tCO2e/year (Loba biotech)
Scope 2 Emissions:3.99 tCO2e/year (pharma&), 129.59 tCO2e/year (Loba biotech)
Scope 3 Emissions:39.96 tCO2e/year (pharma&), 47.12 tCO2e/year (Loba biotech)
Renewable Energy Share:53% (projected by 2024)
Waste Generated:351 tons/year (hazardous waste)
ESG Focus Areas
- Climate protection
- Environmental protection and pollution
- Sustainable procurement and a transparent supply chain
- Health for all
- Patient centering
- Workplace health and safety
- Diversity
- Supply chain
- Attractive and family-friendly employer
- Co-determination and employee representatives
- Careers and further training
- Management and compliance
- Product reliability and quality
- Documentation, communication and risk management
- Combating bribery and corruption
- Preventing conflicts of interest and acting ethically
- Innovation
Environmental Achievements
- 100% of CO2 emissions for 2022 were offset with certificates from Climate Austria.
- Planning to build a photovoltaic power station (125 kW) in 2023 and a hydroelectric power plant (46 kW) in 2024.
Social Achievements
- No work-related accidents at either Loba biotech or pharma& in 2022.
- Continued the Patient Assistance Program (PAP) in the USA, approving 25 cases in 2022.
- Separated HR department from finance department and established it as an independent HR/Law business unit.
Governance Achievements
- No cases of corruption, bribery or other related cases recorded in 2022.
- Planning to hire a dedicated Compliance Manager in 2023.
Climate Goals & Targets
Short-term Goals:
- Complete construction of photovoltaic and hydroelectric plants.
Environmental Challenges
- Increasingly stringent emissions regulations requiring cost-intensive retrofits at Loba biotech’s production facilities.
- Stricter control and reporting regarding production-related emissions due to regulatory requirements (WGC-BREF).
- Potential reputational damage from environmental pollution.
- EU supply chain guidelines requiring respect for human rights in supply chains.
Mitigation Strategies
- Offsetting CO2 emissions with certificates.
- Investing in renewable energy sources (photovoltaic and hydroelectric plants).
- Contract with Energie Klagenfurt GmbH for green electricity supply.
- Supplier survey to identify sustainability measures.
- Implementing comprehensive health and safety measures at Loba biotech.
- Developing a new human resources strategy focusing on employee satisfaction.
Supply Chain Management
Supplier Audits: 75 suppliers surveyed, 53 responses received.
Responsible Procurement
- Supplier survey to assess sustainability practices.
Climate-Related Risks & Opportunities
Transition Risks
- Stringent emissions regulations
Opportunities
- Renewable energy investments
Reporting Standards
Frameworks Used: CSRD, ESRS
Reporting Period: 2023
Environmental Metrics
Total Carbon Emissions:2165.51 tCO2e/year
Scope 1 Emissions:1787.46 tCO2e/year
Scope 2 Emissions:49.9 tCO2e/year
Scope 3 Emissions:153.95 tCO2e/year
Renewable Energy Share:0%
Total Energy Consumption:3565 MWh/year
Waste Generated:192.14 tons/year
ESG Focus Areas
- Climate protection
- Environmental pollution
- Sustainable supply chain
- Workplace health and safety
- Attractive, diverse and family-friendly employer
- Corporate governance and compliance
- Combating bribery and corruption
- Product safety and quality
- Health for all
- Patient centering
Environmental Achievements
- Offset all CO2 emissions for 2023 with certificates from Climate Austria.
- Contracted with Energie Klagenfurt GmbH for green electricity supply to Loba, significantly reducing GHG emissions.
- Planned installation of a 152 kWp photovoltaic system and a 56 kW hydropower plant at Loba in 2024, aiming to increase renewable energy share to 55%.
- Reduced volatile organic compounds (VOC) in Loba's production exhaust air to 300 kg (from 868 kg in 2022).
Social Achievements
- Implemented a 4-day week model in Loba's Microbiology Laboratory.
- Implemented the Whistleblower Protection Act in Q4 2023.
- Continued the Patient Assistance Program (PAP) in the USA, approving 256 cases (vs. 25 in 2022).
- Conducted 253 trainings at Loba in 2023 (vs. 139 in 2022).
Governance Achievements
- Appointed a dedicated Compliance Manager in September 2023.
- Implemented standardized documentation and communication processes at pharma& and Loba.
- Implemented an SOP for quality risk management and conducts regular risk assessments.
Climate Goals & Targets
Medium-term Goals:
- Achieve 55% renewable energy share at Loba with the PV and hydropower plants.
Short-term Goals:
- Complete the test phase of biopharmaceutical production and begin engineering runs by Q2 2024.
- Implement the assessment of mental stress in the workplace in 2024.
- Develop an e-learning platform for Loba Academy.
Environmental Challenges
- Increasingly stringent emissions regulations requiring cost-intensive retrofitting of Loba's production facilities.
- Significant increase in electricity consumption due to the conversion of Loba into a modern biotech site.
- Stricter regulatory requirements for environmental protection and hazardous materials.
- Potential for reputational damage from environmental pollution.
Mitigation Strategies
- Investing in internal processes and expertise to meet regulatory requirements (e.g., WGCBREF).
- Implementing extensive occupational health and safety measures at Loba.
- Planning to introduce a similar occupational health and safety model at pharma&.
- Conducting a supplier survey to assess their sustainability efforts.
Supply Chain Management
Supplier Audits: 75 suppliers surveyed, 53 responded
Responsible Procurement
- Sustainable procurement practices
- Product traceability
Climate-Related Risks & Opportunities
Transition Risks
- Increasingly stringent emissions regulations
Opportunities
- Development of energy-efficient processes
Reporting Standards
Frameworks Used: CSRD, ESRS
Certifications: GMP